The HALT Hepatitis study
Not Applicable
Completed
- Conditions
- Hepatitis C virus (HCV) or B virus (HBV)Infections and InfestationsAcute hepatitis B, Acute hepatitis C
- Registration Number
- ISRCTN24707359
- Lead Sponsor
- niversity College London (UK)
- Brief Summary
2019 results for participants with chronic HCV infection in https://www.ncbi.nlm.nih.gov/pubmed/30929642 (added 24/10/2019)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 660
Inclusion Criteria
Homeless or substance misusing individuals
Exclusion Criteria
1. Individuals unable to give informed consent
2. Under 16 years of age
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> Current primary outcome measures as of 06/12/2012:<br> 1. Cost effectiveness evaluation of the interventions<br> 2. Successfully reaching an appropriate clinical endpoint for those HCV infected<br><br> Previous primary outcome measures until 06/12/2012:<br> 1. Cost effectiveness evaluation of the interventions<br> 2. Successful completion of full HCV clinical diagnosis<br>
- Secondary Outcome Measures
Name Time Method <br> Current secondary outcome measures as of 06/12/2012:<br> 1. Sustained virological response to HCV treatment<br> 2. Successfully reaching an appropriate clinical endpoint, full diagnosis and commencement of treatment, where appropriate, for those HBV infected<br> 3. Proportion of hard-to-reach with adequate immune response to HBV vaccine<br> 4. Factors influencing lack of vaccine uptake<br><br> Previous secondary outcome measures until 06/12/2012:<br> 1. Sustained virological response to HCV treatment<br> 2. Successful full HBV clinical diagnosis and commencement of treatment<br> 3. Proportion of hard-to-reach with adequate immune response to HBV vaccine<br> 4. Factors influencing lack of vaccine uptake<br>